Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)

• Company Description    Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells. Number of Employees: 838

• Price / Volume Information    Yesterday's Closing Price: $1.87 Daily Weekly Monthly 20 Day Moving Average: 9,427,904 shares Shares Outstanding: 333.93 (millions) Market Capitalization: $624.46 (millions) Beta: 0.85 52 Week High: $12.51 52 Week Low: $1.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.52% -20.29% 12 Week -38.89% -48.43% Year To Date -74.73% -76.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD SUITE 400 - SAN CARLOS,CA 94070 USA ph: 650-260-7120 fax: - ir@iovance.com http://www.iovance.com

• General Corporate Information    Officers Frederick G. Vogt - Interim Chief Executive Officer and President; and Jean-Marc Bellemin - Chief Financial Officer and Treasurer Michael Weiser - Director Ryan D. Maynard - Director Wayne Rothbaum - Director Peer Information Iovance Biotherapeutics, Inc. (CORR.) Iovance Biotherapeutics, Inc. (RSPI) Iovance Biotherapeutics, Inc. (CGXP) Iovance Biotherapeutics, Inc. (BGEN) Iovance Biotherapeutics, Inc. (GTBP) Iovance Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 462260100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 333.93 Most Recent Split Date: 9.00 (0.01:1) Beta: 0.85 Market Capitalization: $624.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: 2.94 EPS Growth vs. Year Ago Period: 14.29% vs. Previous Quarter: -38.46% Sales Growth vs. Year Ago Period: 6,798.46% vs. Previous Quarter: -33.07% ROE 06/30/25 - - 03/31/25 - -49.71 12/31/24 - -50.77 ROA 06/30/25 - - 03/31/25 - -39.18 12/31/24 - -39.85 Current Ratio 06/30/25 - - 03/31/25 - 4.18 12/31/24 - 3.74 Quick Ratio 06/30/25 - - 03/31/25 - 3.64 12/31/24 - 3.31 Operating Margin 06/30/25 - - 03/31/25 - -176.49 12/31/24 - -226.84 Net Margin 06/30/25 - - 03/31/25 - -176.49 12/31/24 - -226.84 Pre-Tax Margin 06/30/25 - - 03/31/25 - -178.02 12/31/24 - -228.56 Book Value 06/30/25 - - 03/31/25 - 2.30 12/31/24 - 2.33 Inventory Turnover 06/30/25 - - 03/31/25 - 3.63 12/31/24 - 3.66 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.14

Powered by Zacks Investment Research ©